Katherine Crew, MD, MS, discusses treatment for patients with favorable-risk early-stage HER2-positive breast cancer.
Katherine Crew, MD, MS
Advertisement
Articles by Katherine Crew, MD, MS
Katherine Crew, MD, MS, discusses new research in the advanced HER2-positive breast cancer landscape.
Advertisement
Latest Updated Articles
Dr. Crew on New Research in Advanced HER2+ Breast CancerFebruary 4th 2020
Dr. Crew on Treatment in Favorable-Risk HER2+ Breast CancerFebruary 14th 2020
Advertisement
Advertisement
Trending on OncLive
1
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
2
FDA Grants Priority Review to Subcutaneous Amivantamab in Head and Neck Cancer
3
FDA Awards Orphan Drug Designation to Enzomenib for ALL
4
Dr Barot on the FDA Approval of Palbociclib/Trastuzumab ± Pertuzumab in HER2+ Breast Cancer
5